AFDN

Across TCGA pan-cancer cohorts, AFDN mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of AFDN’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where AFDN mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AFDN is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where AFDN tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AFDN mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−0.528	<.001	9	view →
HNSC	Male	All	−0.439	<.001	9	view →
LSCC	Female	All	−0.765	<.001	8	view →
CCRCC	Male	III,IV	−0.206	<.001	7	view →
PDAC	Female	II,III,IV	−0.364	<.001	5	view →
COAD	All	All	+0.078	.005	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

AFDN–LUAD

Open the LUAD breakdown →